Reduced Risk Across Multiple Cardiometabolic Risk Factors With OLZ/SAM Compared With Olanzapine: Results From a 24-Week Phase 3 Study

MLA

Christine Graham, et al. “Reduced Risk Across Multiple Cardiometabolic Risk Factors With OLZ/SAM Compared With Olanzapine: Results From a 24-Week Phase 3 Study.” Biological Psychiatry, vol. 89, May 2021, p. S339. EBSCOhost, https://doi.org/10.1016/j.biopsych.2021.02.847.

APA

Christine Graham, Arielle D. Stanford, Ying Jiang, Sergey Yagoda, David McDonnell, Christoph U. Correll, Craig Hopkinson, Sarah C. Akerman, Lauren DiPetrillo, & Evan Stein. (2021). Reduced Risk Across Multiple Cardiometabolic Risk Factors With OLZ/SAM Compared With Olanzapine: Results From a 24-Week Phase 3 Study. Biological Psychiatry, 89, S339. https://doi.org/10.1016/j.biopsych.2021.02.847

Chicago

Christine Graham, Arielle D. Stanford, Ying Jiang, Sergey Yagoda, David McDonnell, Christoph U. Correll, Craig Hopkinson, Sarah C. Akerman, Lauren DiPetrillo, and Evan Stein. 2021. “Reduced Risk Across Multiple Cardiometabolic Risk Factors With OLZ/SAM Compared With Olanzapine: Results From a 24-Week Phase 3 Study.” Biological Psychiatry 89 (May): S339. doi:10.1016/j.biopsych.2021.02.847.